A study to compare the study drug IMMU-132 with standard treatments in Metastatic Triple-Negative Breast Cancer patients Who have Received at Least Two Prior Treatments.

Phase 1

• Conditions: Relapsed/Refractory Triple-Negative Breast Cancer; MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2017-003019-21-DE
• Lead Sponsor: Immunomedics, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-27
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 488

Inclusion Criteria

1. Female or male patients, =18 years of age, able to understand and
give written informed consent.
2. Histologically or cytologically confirmed TNBC per ASCO/CAP criteria,
based on the most recent analyzed biopsy or other pathology specimen.
Triple negative is defined as <1% expression for estrogen receptor (ER)
and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) by in-situ hybridization.
3. Metastatic disease documented by CT or MRI imaging.
4. Measurable disease by CT or MRI as per RECIST 1.1. Bone-only disease is not permitted.
5. Brain MRI must be done for patients with brain metastasis and patient must have had stable CNS disease for at least 4 weeks. A maximum of 15% (N=74) of patients with brain metastases will be included in this trial.
Stable brain mets may be defined as:
• Prior local treatment by radiation, surgery, or stereotactic surgery
• Imaging – stable or decreasing size after such local treatment
• Clinically stable signs and symptoms
• =2 weeks from discontinuation of anti-seizure medication.
• Corticosteroid (if needed) - dose should be stable, or decreasing for at
least 2 weeks before randomization. Steroid dose should be 20 mg or
less of prednisone/prednisolone daily, or equivalent of a different
steroid.
6. At least 2 weeks beyond high dose systemic corticosteroids (however,
low dose corticosteroids = 20 mg prednisone or equivalent daily are
permitted provided the dose is stable for 4 weeks).
7. Refractory to or relapsed after at least two prior standard of care chemotherapy regimens for unresectable, locally advanced or metastatic
breast cancer. (These regimens will qualify regardless of triple-negative status at the time they were given. There is no cap on the number of prior chemotherapies for locally advanced or metastatic disease and earlier adjuvant or neoadjuvant therapy for more limited disease will
qualify as one of the required prior regimens if the development of unresectable, locally advanced or metastatic disease occurred within a
12-month period of time after completion of chemotherapy).
a. For patients with a documented germ-line BRCA1/BRCA2 mutation
who received an approved PARP inhibitor, the PARP inhibitor can be
used to meet the criteria for one of two prior standard of care
chemotherapies.
All patients must have been previously treated with a taxane regardless
of disease stage (adjuvant, neoadjuvant or advanced) when it was given. Patients who have contra-indications or are intolerant to taxanes are eligible provided that they received at least one cycle of a taxane and showed contra-indications or intolerance during or at the end of that cycle.
8. Eligible for one of the chemotherapy options listed as TPC (Eribulin, capecitabine, gemcitabine, or vinorelbine) as per investigator assessment.
9. ECOG performance score of 0 or 1.
10. Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, ANC > 1,500 per mm3, platelets > 100,000 per mm3). Blood transfusion or growth factor support is not allowed within 14 days prior to screening labs.
11. Adequate renal and hepatic function (creatinine clearance of > 60
ml/min, may be calculated using Cockcroft-Gault equation; bilirubin = 1.5 IULN, AST and ALT = 2.5 x IULN or =5 x IULN if known liver metastases and serum albumin =3 g/dL).
12. Recovered from all toxicities to Grade 1 or less by NCI CTCAE v4.03
(except alopecia or peripheral neuropathy that m

Exclusion Criteria

1. Women who are pregnant or lactating.
2. Women of childbearing potential or fertile men unwilling to use highly
effective* contraception during study and up to and up to three months
after treatment discontinuation in women of child-bearing potential and
six months in males post last study drug.
3. Patients with Gilbert's disease.
4. Patients with non-melanoma skin cancer or carcinoma in situ of the
cervix are eligible, while patients with other prior malignancies must
have had at least a 3-year disease-free interval.
5. Patients Known to be HIV positive.
6. Patients with hepatitis B positive or hepatitis C positive infection **.
7. Known history of unstable angina, MI, or CHF present within 6 months
of randomization or clinically significant cardiac arrhythmia (other than
stable atrial fibrillation) requiring anti-arrhythmia therapy.
8. Known history of clinically significant active COPD, or other moderateto-
severe chronic respiratory illness present within 6 months of
randomization.
9. Prior history of clinically significant bleeding, intestinal obstruction, or
GI perforation within 6 months of randomization.
10. Infection requiring antibiotic use within one week of randomization.
11. Patients with active chronic inflammatory bowel disease (ulcerative
colitis, Crohn disease) and patients with a history of bowel obstruction
12. Patients who have received a live vaccine within 30 days of
randomization
13. Patients who previously received irinotecan.
14. Rapid deterioration during screening prior to randomization, e.g.
significant change in performance status, = 20% decrease in serum
albumin levels, unstable pain symptoms requiring modifications in
analgesic management.
15. Other concurrent medical or psychiatric conditions that, in the
Investigator's opinion, may be likely to confound study interpretation or
prevent completion of study procedures and follow-up examinations.
*Highly effective is defined as i.e. Combined (estrogen and progestogen
containing) hormonal contraception: oral, intravaginal, transdermal,
progestin -only hormonal contraception associated with inhibition of
ovulation: oral, injectable, implantable, intrauterine device (IUD),
intrauterine hormone-releasing system (IUS), bilateral tubal occlusion,
vasectomized partner, sexual abstinence). Abstinence refers to 'True
abstinence' which means it is in line with the preferred and usual
lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation,
symptotherma, post-ovulation methods), declaration of abstinence for
the duration of exposure to study treatment, and withdrawal are not
acceptable methods of contraception.
** In patients with a history of HBV, hepatitis B core antibody (HBcAb)
testing is required and if positive, then HB DNA testing will be performed
and if positive the patient will be excluded.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified